Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma

Journal of Immunotherapy

Volumn 35, Issue 2, 2012, Pages 189-195

  Li, Jian Jun ^a   Gu, Mo Fa ^a   Pan, Ke ^a   Liu, Li Zhi ^a   Zhang, Hua ^b   Shen, Wei Xi ^c   Xia, Jian Chuan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c SHENZHEN PEOPLE'S HOSPITAL   (China)

Author keywords

adoptive cellular immunotherapy; biological treatment; chemotherapy; cisplatin; cytokine induced killer cells; gemcitabine; metastasis; nasopharyngeal carcinoma

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; ALLERGIC REACTION; ALLERGY; ALOPECIA; ANEMIA; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DISTANT METASTASIS; DRUG EFFICACY; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HEMATURIA; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; KILLER CELL; LEUKOPENIA; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NASOPHARYNX CARCINOMA; NAUSEA AND VOMITING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; CYTOKINE-INDUCED KILLER CELLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS;

EID: 84863167462     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318241d9de     Document Type: Article

References (23)

1. Chan AT, Teo P, Leung TW, et al. The role of chemotherapy in the management of nasopharyngeal carcinoma. Cancer. 1998;82:1003-1012. (Pubitemid 28136512)
2. World Health Organization. International Classification of Tumors: Histological Typing of Upper Respiratory Tract Tumors. Geneva: World Health Organization; 1991.
3. Fandi A, Atum M, Azli N, et al. Nasopharyngeal cancer: Epidemiology, staging, and treatment. Semin Oncol. 1994;21: 382-397. (Pubitemid 24191598)
4. Wang ZJ, Ramcharan S, Love EJ. Cancer mortality of Chinese in Canada. Int J Epidemiol. 1989;18:17-21. (Pubitemid 19128625)
5. Ma BB, Tannock IF, Pond GR, et al. Chemotherapy with gemcitabine- containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer. 2002;95:2516-2523. (Pubitemid 35424037)
6. Leong SS, Wee J, Tay MH, et al. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma. Cancer. 2005;103:569-575.
7. Poon D, Chowbay B, Leong SS, et al. Singapore phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma (NPC). ASCO. 2004;5576.
8. Foo KF, Tan EH, Leong SS, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undiVerentiated type. Ann Oncol. 2002;13:150-156.
9. Ngan RKC, Yiu HHY, Lau WH, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma. Ann Oncol. 2002;13:1252-1258. (Pubitemid 34960134)
10. Zhang L, Zhang Y, Huang PY, et al. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. Cancer Chemother Pharmacol. 2008;61:33-38. (Pubitemid 47512623)
11. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus leukaemia effect. Nat Rev Cancer. 2004;4:371-380. (Pubitemid 38579483)
12. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokineactivated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485-1492. (Pubitemid 16212345)
13. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet. 2000; 356:802-807.
14. Su X, Zhang L, Jin L, et al. Immunotherapy with cytokineinduced killer cells in metastatic renal cell carcinoma. Cancer Biother Radiopharm. 2010;25:465-470.
15. World Health Organization. Handbook for Reporting Results of Cancer Treatment WHO Offset Pub No 48. Geneva: World Health Organization; 1979.
16. National Cancer Institute. Cancer Therapy Evaluation Program, Common Toxicity Criteria Version 20. Bethesda, MD: National Cancer Institute; 1999.
17. Chang JT, Ko JY, Hong RL. Recent advances in the treatment of nasopharyngeal carcinoma. J Formos Med Assoc. 2004;103: 496-510. (Pubitemid 39386607)
18. Ngan RK, Yiu HH, Lau WH, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharygeal carcinoma: Report of phase II study. Ann Oncol. 2002;13:1252-1258. (Pubitemid 34960134)
19. Gritzapis AD, Dimitroulopoulos D, Paraskevas E, et al. Largescale expansion of Cd3 (+)Cd56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants. Cancer Immunol Immunother. 2002;51:440-448. (Pubitemid 35013651)
20. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol. 1991;9:694-704.
21. Shi M, Zhang B, Tang ZR, et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol. 2004;10:1146-1151. (Pubitemid 38559390)
22. Weng DS, Zhou J, Zhou QM, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother. 2008;31:63-71. (Pubitemid 351619405)
23. Leemhuis T, Well S, Scheffold C, et al. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005;11:181-187. (Pubitemid 40287916)